Study of T-PRED(TM) Compared to Pred Forte(R) II
Information source: ISTA Pharmaceuticals
Information obtained from ClinicalTrials.gov on October 19, 2009
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Cataract
Intervention: T-Pred(TM) Ophthalmic Solution (Drug); Pred Forte(R) (Drug)
Phase: Phase 3
Status: Recruiting
Sponsored by: ISTA Pharmaceuticals Official(s) and/or principal investigator(s):
Tim McNamara, PharmD, Study Director, Affiliation: ISTA Pharmaceuticals, Inc.
Overall contact:
Tim McNamara, PharmD, Phone: 949-788-6000, Email: tmcnamara@istavision.com
Summary
Study of T-PRED(TM) Compared to Pred Forte(R)
Clinical Details
Study design: Basic Science, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Crossover Assignment
Primary outcome: Ratio of means aqueous humor prednisolone acetate concentrations
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- 18 years of age or older
Exclusion Criteria:
- No active or adverse disease
Locations and Contacts
Tim McNamara, PharmD, Phone: 949-788-6000, Email: tmcnamara@istavision.com
ISTA Pharmaceuticals, Inc., Irvine, California 92618, United States; Recruiting
Sharon Klier, MD, MPH, Phone: 949-788-6000, Email: sklier@istavision.com
Additional Information
Starting date: February 2009
Last updated: February 26, 2009
|
